Bioxcel therapeutics hosting virtual neuroscience r&d day today

Company to review bxcl502 and other potential emerging pipeline candidates   dr. jeffrey cummings to discuss agitation relief in alzheimer's disease and bxcl502 as a potential treatment for chronic use dr. sandra comer to discuss bxcl501 as a potential treatment for opioid withdrawal new haven, conn., dec. 12, 2023 (globe newswire) -- as previously announced, bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual neuroscience r&d day focused on bxcl502 and other neuroscience pipeline candidates.
BTAI Ratings Summary
BTAI Quant Ranking